Table 5 |
||||
| Sensitivity analyses, age standardised disability-adjusted life years (DALYs) per 100,000 population, and percentage difference (%Diff) as compared to the main analysis, Norway 2008 | ||||
| Cancer sites | Sensitivity analysis 1a | Sensitivity analysis 2b | ||
| DALYs | %Diff | DALYs | %Diff | |
| Lip oral cavity | 46 | 2 | 46 | 2 |
| Nasopharynx | 3 | 0 | 3 | 0 |
| Other pharynx | 33 | 3 | 33 | 3 |
| Oesophagus | 80 | 1 | 80 | 1 |
| Stomach | 152 | 0 | 152 | −1 |
| Colorectum | 643 | 1 | 643 | 0 |
| Liver | 48 | 0 | 48 | 0 |
| Gallbladder | 34 | 0 | 34 | 0 |
| Pancreas | 248 | 0 | 248 | 0 |
| Larynx | 20 | 5 | - c | - c |
| Lung | 864 | 1 | 864 | 0 |
| Melanoma of skin | 180 | 1 | 180 | 0 |
| Kaposi Sarcoma | -d | -d | -d | -d |
| Breast | 587 | 4 | 587 | 3 |
| Cervix uteri | 102 | 1 | 102 | 1 |
| Corpus uteri | 84 | 1 | 84 | 0 |
| Ovary | 151 | 1 | - e | - e |
| Prostate | 364 | 9 | 364 | 4 |
| Testis | 44 | 0 | - e | - e |
| Kidney | 110 | 2 | 108 | 0 |
| Bladder | 105 | 1 | 105 | 1 |
| Brain, nervous system | 281 | 3 | - c | - c |
| Thyroid | 11 | 0 | - e | - e |
| Hematological cancers | - f | - f | - f | - f |
a Sensitivity analysis 1: Two-stage disease model as compared to three stage disease model.
b Sensitivity analysis 2: Proportion of advanced cases used as proxy of patients who did not receive (curatively intentioned) treatment as compared to use of available treatment data.
c Staging data were not available.
d Treatment and staging data were not available.
e Proportion cured was larger than proportion of advanced cases, analysis was not done.
f Sensitivity analyses 1 and 2 were not done for haematological cancers.
Soerjomataram et al. BMC Medical Research Methodology 2012 12:125 doi:10.1186/1471-2288-12-125
